Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 13/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 12/20 | 0.38 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.38 |
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.38 |
| ▸ | NPY4R | P50391 | 2/20 | 0.36 |
| ▸ | NPY1R | P25929 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14887234 | 0.94 | SIRT2 (0.39) | SIRT2SIRT1SIRT3SIRT5NPY4R | |
| SCHEMBL14887476 | 0.94 | SIRT2 (0.39) | SIRT2SIRT1SIRT3SIRT5NPY4R | |
| SCHEMBL19387308 | 0.94 | SIRT2 (0.39) | SIRT2SIRT1SIRT3SIRT5NPY4R | |
| SCHEMBL21604314 | 0.93 | SIRT2 (0.44) | SIRT2SIRT1SIRT3SIRT5NPY4R | |
| SCHEMBL18601941 | 0.93 | SIRT2 (0.38) | SIRT2SIRT1SIRT3SIRT5NPY4R | |
| SCHEMBL20224658 | 0.93 | SIRT2 (0.38) | SIRT2SIRT1SIRT3SIRT5NPY4R | |
| SCHEMBL16455203 | 0.92 | SIRT2 (0.39) | SIRT2SIRT1SIRT3SIRT5NPY4R | |
| SCHEMBL19387304 | 0.92 | SIRT2 (0.37) | SIRT2SIRT1SIRT3SIRT5NPY4R | |
| SCHEMBL19687946 | 0.92 | SIRT2 (0.39) | SIRT2SIRT1SIRT3SIRT5NPY4R | |
| SCHEMBL15606241 | 0.92 | SIRT2 (0.38) | SIRT2SIRT1SIRT3SIRT5NPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160022829-A1 | TUBULYSIN COMPOUNDS AND CONJUGATES THEREOF | MERSANA THERAPEUTICS, INC. | 2016-01-28 | — | — | US | disclosed |
| WO-2014160360-A1 | TUBULYSIN COMPOUNDS AND CONJUGATES THEREOF | MERSANA THERAPEUTICS INC. (US) | 2014-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022829-A1 | TUBULYSIN COMPOUNDS AND CONJUGATES THEREOF | LGMN, TLL1, TEK | SIRT2 4034/4885SIRT1 3938/4885SIRT3 3661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.